Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martino Maddalena

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nature Communications|June 23, 2021
Inhibition of MRN activity by a telomere protein motifFreddy Khayat, Elda Cannavo, Majedh Alshmery, et al.
Cancer Cell|June 13, 2025
Senescence in cancerManuel Colucci, Miles Sarill, Martino Maddalena, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 5, 2021
<i>TP53</i> missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironmentMartino Maddalena, Giuseppe Mallel, Nishanth Belugali Nataraj, et al.
Nature Communications|May 19, 2022
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patientsOri Hassin, Nishanth Belugali Nataraj, Michal Shreberk-Shaked, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2022
Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteinsSaptaparna Mukherjee, Martino Maddalena, YiQing Lü, et al.
Journal of Hazardous Materials|July 4, 2024
Carcinogenic health outcomes associated with endocrine disrupting chemicals exposure in humans: A wide-scope analysisBin Zeng, Yuwei Wu, Yin Huang, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Nature Cancer|July 17, 2023
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cellsDaniela Brina, Adele Ponzoni, Martina Troiani, et al.
Cancer Cell|September 20, 2024
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancerBianca Calì, Martina Troiani, Silvia Bressan, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nature Communications|June 23, 2021
Inhibition of MRN activity by a telomere protein motifFreddy Khayat, Elda Cannavo, Majedh Alshmery, et al.
Cancer Cell|June 13, 2025
Senescence in cancerManuel Colucci, Miles Sarill, Martino Maddalena, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 5, 2021
<i>TP53</i> missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironmentMartino Maddalena, Giuseppe Mallel, Nishanth Belugali Nataraj, et al.
Nature Communications|May 19, 2022
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patientsOri Hassin, Nishanth Belugali Nataraj, Michal Shreberk-Shaked, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2022
Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteinsSaptaparna Mukherjee, Martino Maddalena, YiQing Lü, et al.
Journal of Hazardous Materials|July 4, 2024
Carcinogenic health outcomes associated with endocrine disrupting chemicals exposure in humans: A wide-scope analysisBin Zeng, Yuwei Wu, Yin Huang, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Nature Cancer|July 17, 2023
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cellsDaniela Brina, Adele Ponzoni, Martina Troiani, et al.
Cancer Cell|September 20, 2024
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancerBianca Calì, Martina Troiani, Silvia Bressan, et al.
Pageof 1